PDCD1 and myelodysplastic syndrome: A randomized phase 2 trial of azacitidine with or without durvalumab, an antibody that binds PD-L1 and blocks PD-1/PD-L1 interaction, as a first-line therapy for higher-risk MDS did not show significant improvement in clinical outcomes over azacitidine alone, while demonstrating higher rates of toxicities in the ICI combination arm [70].